74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Alkermes PLC
Closed
SectorHealthcare
34.42 1.38
Overview
Share price change
24h
Min
33.98
Max
34.6
Income | 54M 147M |
|---|---|
Sales | 52M 430M |
P/E Sector Avg | 15.623 71.874 |
EPS | 1.05 |
Profit margin | 34.072 |
Employees | 1,800 |
EBITDA | 58M 181M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +13.86% upside |
Next Earnings | 30 Apr 2025 |
|---|
Market Cap | 487M 5.6B |
|---|---|
Previous open | 33.04 |
Previous close | 34.42 |
News Sentiment
By Acuity
50%
50%
174 / 387 Healthcare
Technical Score
By Trading Central
Confidence
Bullish Evidence
Alkermes PLC Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Alkermes PLC Forecast
Price Target
By TipRanks
13.86% upside
12 Months Forecast
Average 38.62 USD 13.86%
High 46 USD
Low 30 USD
Based on 13 Wall Street analysts offering 12 month price targets forAlkermes PLC - Dist in the last 3 months.
Sentiment
By Acuity
174 / 387 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Alkermes PLC
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.
